DDInter302 DDInter1376
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Carmustine {u} (Compound) treats {v} (Disease) melanoma
Carmustine {u} (Compound) binds {v} (Gene) CYP1A2
Carmustine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Carmustine {u} (Compound) causes {v} (Side Effect) Vision blurred
Carmustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Carmustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Carmustine {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Carmustine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Carmustine (Compound) treats melanoma (Disease)
Carmustine (Compound) binds CYP1A2 (Gene)
Carmustine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Carmustine (Compound) causes Vision blurred (Side Effect)
Carmustine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Carmustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Carmustine may lead to a major life threatening interaction when taken with Cladribine